A hospital worker who had received both doses of COVID-19 vaccine between late January and early February was the first case of coronavirus transmission detected in China since February, state media report today.
The victim, named after Liu, had been working in the quarantine department of Xi’an Hospital since March 4 and was primarily responsible for collecting samples from quarantined people for diagnostic tests, the Health Times reported.
This newspaper belongs to the People’s Daily group, the official newspaper of the Chinese Communist Party.
China announced on Thursday the case, which is the first domestic transmission detected in the country since February 14.
The Health Times added, citing a team of experts in Shanxi Province, where Xi’an City is located, that Liu was infected after being accidentally exposed to the virus while in the hospital’s quarantine area.
The paper also quoted Zheng Guang, a former chief epidemiologist at China’s Centers for Disease Control and Prevention, as saying that the vaccine protection rate was “not 100%” and that it was “relatively safe” rather than “absolutely safe”, but people should not question domestic vaccines because of this case.
“The effectiveness of home-based vaccines in preventing serious cases in China is more than 90% and the overall protection rate is more than 70%,” Zeng said, adding that hospitals dealing with COVID-19 cases are high-risk areas where vaccinated health personnel cannot rule out the possibility of infection.
Thirty-three quarantine workers along with Liu tested negative for molecular tests. They have been quarantined and under medical supervision.
The Health Times did not specify which vaccine was given to Liu.
China currently has four domestic vaccines against COVID-19 for public use, along with vaccines developed by CanSino Biologics Inc. (CanSinoBIO) and the Wuhan Institute of Biological Products, a subsidiary of the Chinese National Pharmaceutical Group (Sinopharm), which received approval in February.
This was followed by a vaccine from Sinovac Biotech, which was also approved last month, and another, that of the Sinopharm plant in Beijing, which was approved last year.
A fifth vaccine being developed by the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) has also been approved for emergency use in China, the institute announced on March 15.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
.jpg "Chronic obstructive bronchopneumopathy, give me the La TV series to get to know a disease better that represents the third cause of death in the world")
